Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Oruka Therapeutics, Inc.ABIO · Entity 3781 | Director · Pres. & Chief Executive Offic | December 14, 2021 | December 16, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Oruka Therapeutics, Inc.
Report date December 14, 2021 · Filed December 16, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.29 · Expires 2031-12-14 | Direct | 95,000 |
Reported balance
After 2021-12-14 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-12-14 · Grant · Acquired 95,000 · Balance 95,000 F1: Grant to the Reporting Person of a stock option under the 2020 Equity Incentive Plan (the Plan), vesting in 36 equal monthly installments from the date of grant, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan prior to such time. In the event of a change in control of the Issuer, 50% of the unvested options shall become fully and immediately vested upon the closing date of such change in control, provided, however, that on the earlier of (i) the one-year anniversary of the closing date or (ii) involuntary termination, any options that remain unvested on such earlier date shall become fully and immediately vested. |
| Common StockSEC Table I · non-derivative | IndirectBy InvestocorTrust as sole Trustee | 1,109 |
Reported balance
Holding disclosure · report date 2021-12-14 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,109 |
| Common StockSEC Table I · non-derivative | IndirectBy NFS Custodian for Michael Bristow's IRA | 1,414 |
Reported balance
Holding disclosure · report date 2021-12-14 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,414 |
| Common StockSEC Table I · non-derivative | Direct | 2,285 |
Reported balance
Holding disclosure · report date 2021-12-14 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 2,285 |
Filing footnotes · ownership attribution and instrument terms
F1: Grant to the Reporting Person of a stock option under the 2020 Equity Incentive Plan (the Plan), vesting in 36 equal monthly installments from the date of grant, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan prior to such time. In the event of a change in control of the Issuer, 50% of the unvested options shall become fully and immediately vested upon the closing date of such change in control, provided, however, that on the earlier of (i) the one-year anniversary of the closing date or (ii) involuntary termination, any options that remain unvested on such earlier date shall become fully and immediately vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 14, 2021 Filed Dec 16, 2021 21:31 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | GrantStock Option (right to buy) · Derivative | 95,000 | $0.00 Strike: $2.29 | $0.00 |
DisclosureSEC source: 0001209191-21-069960 · doc4.xml · derivative · entry 4 BRISTOW MICHAEL R · CIK 0001266125 · Director · Pres. & Chief Executive Offic 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 95,000 shares Expires 2031-12-14 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the 2020 Equity Incentive Plan (the Plan), vesting in 36 equal monthly installments from the date of grant, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan prior to such time. In the event of a change in control of the Issuer, 50% of the unvested options shall become fully and immediately vested upon the closing date of such change in control, provided, however, that on the earlier of (i) the one-year anniversary of the closing date or (ii) involuntary termination, any options that remain unvested on such earlier date shall become fully and immediately vested. Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 21:15 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | GrantStock Option (right to buy) · Derivative | 190,000 | $0.00 Strike: $4.27 | $0.00 |
DisclosureSEC source: 0001209191-20-065002 · doc4.xml · derivative · entry 4 BRISTOW MICHAEL R · CIK 0001266125 · Director · Pres. & Chief Executive Offic 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,000 Underlying: Common Stock · 190,000 shares Expires 2030-12-21 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the 2020 Equity Incentive Plan (the Plan), vesting in 48 equal monthly installments from the date of grant, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan prior to such time. In the event of a change in control of the Issuer, 50% of the unvested options shall become fully and immediately vested upon the closing date of such change in control, provided, however, that on the earlier of (i) the one-year anniversary of the closing date or (ii) involuntary termination, any options that remain unvested on such earlier date shall become fully and immediately vested. Read SEC document |
| April 04, 2017 Filed Apr 5, 2017 20:14 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | SaleCommon Stock | 720 | $2.41 | $1,735.20 |
DisclosureSEC source: 0001209191-17-025617 · doc4.xml · nonDerivative · entry 1 BRISTOW MICHAEL R · CIK 0001266125 · Director · Pres. & Chief Executive Offic 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,155 F1 · shares: Represents shares of common stock sold pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person with respect to the vesting of previously reported Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's 2013 Amended and Restated Equity Incentive Plan (the "Plan"). F2 · balance_after: Includes (i) remaining 2,025 previously reported shares issued as RSUs under the Plan that vest on 2/27/18, and (ii) remaining 2,291 previously reported shares issued as RSUs under the Plan that vest on 4/2/18, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined under the Plan; and 36,839 previously reported shares of common stock held directly. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 22:10 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | SaleCommon Stock | 763 | $2.61 | $1,991.43 |
DisclosureSEC source: 0001209191-17-015978 · doc4.xml · nonDerivative · entry 1 BRISTOW MICHAEL R · CIK 0001266125 · Director · Pres. & Chief Executive Offic 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,875 F1 · shares: Represents shares of common stock sold pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person with respect to the vesting of previously reported Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's 2013 Amended and Restated Equity Incentive Plan (the "Plan") F2 · balance_after: Includes (i) remaining 2,025 previously reported shares issued as RSUs under the Plan that vest on 2/27/18, and (ii) 4,581 previously reported shares issued as RSUs under the Plan that vest in two equal annual installments beginning 4/2/17, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined under the Plan; and 35,269 previously reported shares of common stock held directly. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 22:10 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | GrantStock Option (right to buy) · Derivative | 41,600 | $0.00 Strike: $2.60 | $0.00 |
DisclosureSEC source: 0001209191-17-015978 · doc4.xml · derivative · entry 4 BRISTOW MICHAEL R · CIK 0001266125 · Director · Pres. & Chief Executive Offic 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,600 Underlying: Common Stock · 41,600 shares Expires 2027-02-26 F3 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Plan, 50% vesting upon achievement of certain pre-specified corporate milestone related to the outcome of the interim data analysis by that trial's Data and Safety Monitoring Board, and if the milestone is achieved, the remainder of the grant will vest on March 31, 2018, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan prior to such time. If the corporate milestone is not achieved, the Option will be cancelled. In the event of a change in control of the Issuer, 50% of the unvested options shall become fully and immediately vested upon the closing date of such change in control, provided, however, that on the earlier of (i) the one-year anniversary of the closing date or (ii) involuntary termination, any options that remain unvested on such earlier date shall become fully and immediately vested. Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 21:49 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | GrantStock Option (right to buy) · Derivative | 42,000 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001209191-17-012757 · doc4.xml · derivative · entry 4 BRISTOW MICHAEL R · CIK 0001266125 · Director · Pres. & Chief Executive Offic 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 42,000 shares Expires 2027-02-15 F2 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Plan, vesting in 36 equal monthly installments from the date of grant, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan prior to such time. In the event of a change in control of the Issuer, 50% of the unvested options shall become fully and immediately vested upon the closing date of such change in control, provided, however, that on the earlier of (i) the one-year anniversary of the closing date or (ii) involuntary termination, any options that remain unvested on such earlier date shall become fully and immediately vested. Read SEC document |
| September 20, 2016 Filed Sep 21, 2016 20:09 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | SaleCommon Stock | 1,972 | $2.89 | $5,699.08 |
DisclosureSEC source: 0001209191-16-142261 · doc4.xml · nonDerivative · entry 1 BRISTOW MICHAEL R · CIK 0001266125 · Director · Pres. & Chief Executive Offic 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,638 F1 · shares: Represents shares of common stock sold pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person with respect to the vesting of previously reported Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's 2013 Amended and Restated Equity Incentive Plan (the "Plan") F2 · price: The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions ranged from $2.88 to $2.89. Upon request of the SEC staff, ARCA biopharma, Inc. (the "Company") or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes (i) remaining 4,050 previously reported shares issued as RSUs under the Plan that vest in two equal annual installments beginning on 2/27/17, and (ii) 4,581 previously reported shares issued as RSUs under the Plan that vest in two equal annual installments beginning 4/2/17, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined under the Plan; and 34,007 previously reported shares of common stock held directly. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.